abstract BACKGROUND AND OBJECTIVES: Cytomegalovirus (CMV) is the most common congenital infection and nongenetic cause of congenital sensorineural hearing loss in the United States. Utah was the first state to pass legislation mandating CMV screening for newborns who fail newborn hearing screening (NBHS). The study objective was to present outcomes of hearing-targeted CMV screening and determine factors predicting CMV screening.
Cytomegalovirus (CMV) is the most common congenital infection, with a prevalence of 0.3% to 1.2% in industrialized nations, and is the most common nongenetic cause of congenital sensorineural hearing loss (SNHL) in the United States. 1 -3 Although the exact magnitude is unclear, 6% to 30% of pediatric hearing loss may be attributed to congenital CMV (cCMV). 2, 4 -7 Congenital CMV often goes undetected at birth because most newborns are "asymptomatic" with no obvious clinical signs or symptoms other than a possible failed newborn hearing screen (NBHS), although 10% to 15% of these asymptomatic infants have or will develop SNHL. 8, 9 For the purposes of this study, infants with no clinical symptoms other than isolated hearing loss were considered asymptomatic because the only way to identify them was through CMV screening or hearing screening followed by CMV screening. Targeted screening of infants for cCMV based on a failed NBHS (hearing targeted early CMV screening; HT-CMV) is 1 approach for early detection of asymptomatic cCMV. Although the cost for CMV screening is higher than cost estimates for other newborn screening tests, few infants are tested in an HT-CMV approach, making the CMV screening process more similar to diagnostic testing than to screening. As such, CMV screening appears to be relatively low cost compared with diagnostic testing, although the impact on health outcomes have not yet been examined. 10, 11 In 2013, Utah became the first state to enact a CMV public health initiative on CMV education and testing (UCA 26-10-10). 12 The first provision of the law charged the Utah Department of Health with creating an education program about birth defects associated with and ways to prevent cCMV. This program has an approximate annual budget of $30 000 and targets women of childbearing ages, as well as child care and health care providers. The second provision mandates that all infants who fail their NBHS be tested for CMV within the first 3 weeks of life unless a parent declines the test. The 21-day period is required to differentiate cCMV from postnatally acquired CMV, which is not associated with childhood hearing loss. 1, 13, 14 The associated Rule (R398-4) further clarifies eligibility criteria for CMV screening as those infants who fail both their inpatient and return outpatient screening or those infants who fail their first hearing screening if it occurs after age 14 days. The legislation was designed to identify asymptomatic infants most at risk for hearing loss: those who fail NBHS. 15, 16 In special populations where NBHS(s) cannot be accomplished before 21 days of age (such as those in the NICU), testing for cCMV is left to the discretion of the medical practitioner(s) caring for the newborn.
The Utah law is serving as a model for actions in other states. In 2015, Connecticut enacted legislation that mirrors Utah's mandatory testing provision for newborns. 17 Texas, Tennessee, Hawaii, and Illinois enacted legislation to increase cCMV educational efforts; Illinois now provides information on testing options for cCMV and early intervention. 18 -21 The results of Utah's work are timely and have implications for national public policy. The goal of this study is to present the results from the first 2 years after Utah's legislation and determine which sociodemographic and health care characteristics are related to compliance for timely CMV screening and diagnostic hearing evaluation.
METHODS

Data
The data for the current study were drawn from 2 sources: the Utah Department of Health's Early Hearing Detection and Intervention (EHDI) Tracking and Data Management System (HiTrack) and the Utah Vital Records database for births that occurred in the 24 months before and after the implementation of the law on July 1, 2013. The number of infants who failed their NBHS and the number of infants eligible who actually underwent CMV screening were determined from Utah's EHDI HiTrack database. Out of 103 868 births, 705 newborns (0.7%) failed their inpatient and subsequent NBHS or failed their first hearing screen after age 14 days and were eligible for CMV screening according to the legislation. Nationally, ∼1.6% of infants failed their final NBHS in 2013. 22 Potential factors that may influence successful early CMV screening were obtained from Vital Records. Sixteen records were dropped because of missing data on mother's education and thus, 689 infants had vital records data. Not included in the current study were infants in special populations such as those in the NICU who had NBHS after 21 days. Thirteen infants with symptomatic cCMV (ie, those who showed clinical symptoms at birth that led to CMV screening such as thrombocytopenia, petechiae, hepatomegaly, splenomegaly, intrauterine growth restriction, hepatitis, or central nervous system involvement) were all in the NICU and not included in the current study because the focus of the legislation was on infants who failed NBHS. The study was approved by the Institutional Review Boards at Primary Children's Hospital, the University of Utah, and the Utah Department of Health.
Statistical Methods
Descriptive statistics on the sociodemographic characteristics of mothers and the hearing screening that led to CMV screening eligibility and the national EHDI 3-month diagnostic audiologic follow-up milestone attainment were examined. Multivariate logistic regression analyses, appropriate for dichotomous outcomes, assessed what characteristics were linked to the likelihood of the infant undergoing (1) CMV screening by 3 weeks of age and (2) an audiological diagnostic evaluation by 3 months of age. The events-to-variable ratio was >10 for all analyses involving logistic regression. The odds ratios (ORs) generated from such regressions can be interpreted as the effect of being in a specific category relative to the reference group on the odds of the outcome in question, holding all other covariates constant. 23 Collinearity diagnostics undertaken as part of the multivariate analyses revealed no causes for concerns regarding multicollinearity among the independent variables. Figure 1 shows the various CMV screening patterns for those who were eligible for CMV screening according to the HT-CMV legislation because of an inpatient and outpatient failed screen or an initial failed screen after 14 days. One hundred eighty infants passed a subsequent hearing screen and were not referred for CMV screening (and excluded from subsequent analyses). Fourteen (6.0%) of the 234 infants tested within 21 days of birth were positive, and 6 (42.9%) of those had confirmed hearing loss. The type of CMV test varied and is indicated in Fig 1. Saliva samples for CMV screening were taken at least 60 minutes after breastfeeding. 24 Seven (8.8%) of the 80 infants tested after 21 days were CMV positive, and 3 (42.9%) of those had confirmed hearing loss. Table 1 provides descriptive information on the mothers and their infants born both before and after the legislation who never passed a NBHS. Mothers whose infants failed NBHS (and were referred for CMV screening after the legislation) were more likely than the population of all births to be younger than 29 years of age, not married, have less than a college education, have the birth covered by Medicaid, have a nonhospital birth, and live away from the urban Wasatch Front. Figure 2 illustrates the 90-day diagnostic hearing evaluation patterns for the infants who failed their NBHS(s) after the law. After the legislation, 77% of all infants received timely diagnostic hearing evaluation (compared with 56% in the 24 months before the legislation). After the law, among the infants who received a CMV test, 272 of 314 (86.6%) had the diagnostic hearing evaluation within 90 days, compared with 120 of 195 (61.5%) infants who did not receive a CMV test (see Fig 3) . After the legislation, 54% of the infants who had diagnostic hearing evaluations after 90 days had comorbidities (eg, chronic otitis media with or without cleft lip and palate) that delayed final audiological determination.
RESULTS
Descriptive Statistics
Among all infants who completed a diagnostic hearing evaluation after the legislation, 218 (50.2% of 434 infants) were found to have had normal hearing, whereas 215 (49.5% of 434 infants) were confirmed to have a hearing loss. Eighty-five infants had SNHL, 19 mixed, 87 conductive hearing loss, 5 auditory neuropathy spectrum disorder, and 19 undetermined. Eighty-five percent of infants diagnosed with SNHL had CMV screening completed.
Multivariate Analyses
Multivariate analyses examined the sociodemographic and health care variables associated with achieving CMV screening compliance ( Table 2) and the 3-month hearing diagnostic target ( Table 3) . We examined the sociodemographic and NBHS protocol predictors of infants completing CMV screening within 21 days of birth.
The multivariate analyses showed an OR of 0.23 (confidence interval [CI] 0.11-0.51), indicating the odds of CMV screening was 77% lower for infants who received 2 screens, at least 1 of which occurred after 14 days of birth (n = 9 infants; 10% of those who had 2 screens with at least 1 after 14 days) compared with those infants who underwent the recommended 2 screenings within 14 days of birth (n = 162; 66% of those who had 2 screens within 14 days of birth). The odds of an infant getting CMV screening for those born in the first 6 months after the law was enacted were 64% lower than those born after the first 6 months (OR = 0.36, CI = 0.23-0.57). The odds of an infant getting CMV tested were 1.84 times higher (CI = 1.17-2.89) for infants born to a mother with a 4 by guest on January 28, 2018 http://pediatrics.aappublications.org/ Downloaded from bachelor's degree or higher relative to those with less than a bachelor's degree. The location of the infant's birth was also associated with the odds of undergoing CMV screening within 21 days of birth; the odds of an infant receiving CMV screening were 69% lower (OR = 0.31, CI = 0.15-0.63) for infants born outside a hospital compared with those born in a hospital.
In Table 3 , we present the logistic regression OR estimates of factors associated with eligible infants undergoing a diagnostic hearing evaluation by 3 months of age for all infants born 24 months before and 24 months after the legislation was enacted. Two multivariate models are estimated. The first model adjusts for the different CMV screening patterns with the reference group being infants born before the CMV law went into effect. The second model provides a strict test of the law's impact on the likelihood of complying with the 3-month diagnostic hearing evaluation regardless of the pattern of CMV screening.
Column 3 in Table 3 reveals that timely diagnostic hearing evaluation rates improved after the legislation from 56% to 77%. Model 2 shows that the odds of an infant receiving a timely diagnostic hearing evaluation were 2.75 times higher (CI = 2.08-3.64) for those infants born after the law compared with those born before the legislation. Model 1 demonstrates that the pattern of CMV screening was related to the odds of undergoing a timely diagnostic evaluation. Although all
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FIGURE 2
Three-month diagnostic hearing evaluation fi gures for Utah infants who failed their NBHS and were asymptomatic for CMV for the 24-month period after enactment of the law (July 2013-June 2015). a Infants whose diagnostic evaluations were still in process had received at least 1 diagnostic evaluation but had not yet received a confi rmed diagnosis.
FIGURE 3
Numbers of infants who completed diagnostic hearing evaluations within 90 days by CMV testing status.
by guest on January 28, 2018 http://pediatrics.aappublications.org/ Downloaded from infants were more likely to undergo timely diagnostic evaluation after the legislation compared with those born before the law, the magnitude of the OR varied by CMV screening pattern. Infants who underwent CMV screening within 21 days were >5 times as likely to have timely diagnostic testing done relative to those born before the CMV screening legislation was enacted (OR = 5.46, CI = 3.52-8.48). In contrast, the effect size, although still positive, is smaller for infants who were tested after 21 days and infants who did not undergo CMV testing. These differences in magnitude across the groups may reflect a "compliance effect" in which parents who comply with the CMV testing also comply with the 3-month diagnostic hearing evaluation recommendation. Models 1 and 2 reveal that several sociodemographic factors were also linked to the odds of meeting the diagnostic recommendations. Mothers with college degrees and married mothers had greater odds of completing diagnostic testing by 3 months of age relative to mothers with less education and unmarried mothers. Births covered by Medicaid were more likely to comply with the 3-month diagnostic testing recommendation than those births not covered by Medicaid. Conversely, the odds of an infant completing timely diagnostic testing were lower for those who had a nonhospital birth compared with infants born in the hospital. The odds of an infant completing timely diagnostic testing were also lower for children with siblings compared with only children.
DISCUSSION
This study is the first to assess the implementation of a statewide HT-CMV screening of infants after the enactment of CMV legislation. Fourteen infants were identified as CMV-positive within 21 days after birth; 6 had hearing loss. It is highly likely that these asymptomatic cCMV infected children would not have been diagnosed at a later time because of the difficulty distinguishing postnatally acquired 6 by guest on January 28, 2018 http://pediatrics.aappublications.org/ Downloaded from CMV from cCMV after 3 weeks of age from urine or saliva. Alternative approaches to cCMV diagnosis at a later date by using archived neonatal dried blood spot (DBS) polymerase chain reaction testing may be an appropriate testing strategy for infants with hearing loss, depending on the sensitivity of the DBS assay used and length of storage of DBS neonatal Guthrie cards. 25, 26 Identification of asymptomatic CMV-positive children provides opportunities for focused surveillance. Fowler and others have shown that cCMV positive infants are at risk for delayed onset, fluctuating, and progressive SNHL. 7 -9, 16 This risk has been reported to be 8% to 15% or higher for asymptomatic cCMV. 16, 27 Repeated hearing testing of cCMV children also provides an opportunity to detect changes in hearing thresholds and provide earlier intervention. Furthermore, HT-CMV screening may improve the diagnosis of symptomatic cCMV infected infants. Future research should examine the hypothesis that HT-CMV screening improves the diagnosis of not only asymptomatic but also symptomatic cCMV infants.
Infants born after the CMV legislation were significantly more likely to undergo diagnostic hearing evaluation by 3 months of age than infants born before the HT-CMV legislation. Educational campaigns and urgency surrounding CMV also may have increased awareness of the importance of timely diagnostic hearing evaluation. Delays in the diagnosis and treatment of hearing loss are a major challenge for universal NBHS programs. Thus, HT-CMV screening has implications not just for CMV infected but for all infants who are hard of hearing. Several studies have demonstrated improved language outcomes when children who are hard of hearing 7 are diagnosed and treated before 6 months of age. 28 -30 We found parents of infants who complied with the CMV testing recommendations were more likely to comply with the recommendation of having the infant undergo a diagnostic evaluation in a timely manner. This finding suggests that educational efforts and systems should target CMV noncompliers; identifying infants who failed to be tested for CMV in a timely manner may be important for improving timely diagnostic hearing rates by targeting this hard-to-reach group. 
